All Journals

Dedicated to advancing clinical, translational, and surgical cancer research. The journal serves oncologists, hematologists, surgical and radiation oncologists, cancer biologists, and translational scientists with rigorous, internationally accessible scholarship across the cancer continuum, from molecular pathogenesis to diagnosis, treatment, and survivorship. We welcome original research, systematic reviews and meta-analyses, case reports, and editorials spanning tumor biology, cancer biomarkers and liquid biopsy (circulating tumor DNA, cell-free DNA, microRNAs), molecular cytogenetics, hematological malignancies (multiple myeloma, DLBCL and other lymphomas), surgical and interventional oncology, pediatric oncology, translational pharmacology including phytochemical and inflammasome research, and emerging artificial intelligence applications in cancer screening and diagnostics. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, and each is assigned a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint for harvesting. The journal adheres to COPE ethical principles and supports global research equity through article-processing-charge waivers and discounts, ensuring authors from all regions can disseminate high-impact cancer research to a worldwide readership.

Publishes rigorous original scholarship on the biology, diagnosis, treatment, and epidemiology of leukemias and related hematologic malignancies, serving hematologists, oncologists, pathologists, translational scientists, and clinical investigators worldwide. The journal welcomes work across acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), and myelodysplastic syndromes (MDS), as well as clonal hematopoiesis and pre-leukemic states. Core topics include leukemia genomics and biomarkers, cytogenetics, flow-cytometric immunophenotyping, measurable residual disease, risk stratification, targeted and immunotherapeutic agents, stem-cell transplantation, and the environmental and occupational determinants of leukemia, including benzene and other genotoxic exposures. We consider original research, systematic reviews and meta-analyses, narrative reviews, case reports, and editorials. Every submission undergoes double-blind peer review in line with COPE ethical principles. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and harvestable via the journal's OAI-PMH endpoint.

TJORO welcomes original research, reviews, case reports, and technical notes spanning image-guided radiotherapy (IGRT), cone-beam and MRI-guided adaptive radiotherapy, stereotactic body radiation therapy (SBRT) and radiosurgery (SRS), volumetric modulated arc therapy, proton therapy, treatment planning, and management of toxicity such as radiation dermatitis. Outcomes in brain metastases, oligometastatic disease, and primary CNS lymphoma are core interests. Every submission undergoes double-blind peer review. Accepted articles are open access under a Creative Commons Attribution (CC-BY 4.0) licence, authors retain copyright, and each gets a permanent Crossref DOI. Content is discoverable via OpenAlex and Google Scholar and harvestable through an OAI-PMH endpoint; the journal follows COPE principles, with article-processing charges on acceptance and waivers available.

Advances the evidence base of clinical oncology by publishing rigorous original research, systematic reviews and meta-analyses, instructive case reports, and editorials that bridge laboratory discovery and bedside practice. The scope spans the breadth of solid tumors and hematologic malignancies, including breast, thoracic, colorectal, and rare cancers such as leiomyosarcoma, phyllodes tumors, and carcinoma of unknown primary. Core themes include chemotherapy and immunotherapy outcomes, multidrug resistance and novel drug-delivery strategies, cardio-oncology and anthracycline cardiotoxicity, molecular diagnostics including mismatch-repair and microsatellite-instability testing, and supportive and survivorship care. We particularly welcome well-documented clinical case reports of diagnostic dilemmas and rare presentations, alongside translational and precision-oncology studies. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles to safeguard integrity of the scholarly record.

Disseminates original, internationally relevant scholarship across the spectrum of clinical cancer research, bridging laboratory discovery, diagnosis, treatment, and patient outcomes for a global readership of oncologists, surgeons, radiologists, nuclear-medicine specialists, pathologists, and translational cancer scientists. The journal welcomes original research, reviews, case reports, and editorials on solid and hematologic malignancies, including hepatocellular carcinoma and locoregional therapies, interventional and nuclear oncology (transarterial radioembolization, Y-90 dosimetry and microspheres), prostate cancer and hormonal therapy, rare and odontogenic tumors, cancer survivorship and quality of life, early detection and screening, and environmental oncology. We also publish translational and mechanistic studies spanning tumor biology, biomarkers, nanoparticle-based therapeutics, and cancer prevention, alongside clinical-trial reports and methodological work that informs practice and policy. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint, and the journal follows COPE ethical principles to safeguard the integrity of the scholarly record.

Dedicated to disseminating original research across tumor biology, cancer diagnostics, and therapeutics. The journal serves as an internationally accessible platform connecting basic scientists, translational researchers, and clinical oncologists working to understand and treat human cancers. We publish work spanning molecular and cellular oncology, the tumor microenvironment, cancer biomarkers and risk stratification, genomic alterations (including p53, RAD51B, and HER2-driven tumors), and emerging therapeutics such as PARP inhibitors, anti-angiogenic and anti-mitotic agents, and drug-repurposing strategies. Clinically oriented subfields include urologic oncology (prostate and bladder cancer, hematuria, cystoscopy), gastrointestinal and colorectal cancer, gynecologic and peritoneal malignancies managed with cytoreductive surgery and HIPEC, head and neck squamous cell carcinoma, and AIDS-defining cancers. The journal welcomes original research, systematic and narrative reviews, case reports, methodological studies, and editorials. Submissions are evaluated through rigorous double-blind peer review to ensure scientific integrity and methodological soundness. All accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, are assigned a permanent Crossref DOI, and are made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, in line with COPE ethical principles.

Dedicated to the study of blood and blood-forming tissues across the full breadth of hematology. The journal advances scholarship in both malignant and non-malignant disease, serving hematologists, oncologists, transfusion-medicine specialists, laboratory scientists, and translational researchers worldwide. The journal welcomes original research, systematic reviews, clinical studies, case reports, and editorials spanning hematologic malignancies (leukemia, lymphoma, myeloproliferative neoplasms such as myelofibrosis and essential thrombocythemia), thrombosis and hemostasis (including direct oral anticoagulants and their reversal), anemia and red cell disorders, hemoglobinopathies, immunohematology and transfusion medicine, and hematology pharmacogenomics (for example TPMT and thiopurine drug safety). We value rigorous methodology, reproducible data, and clinically meaningful insight, from bench-side molecular work to bedside management and population studies. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and are assigned a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and harvestable via OAI-PMH, and the journal follows COPE ethical principles to safeguard the integrity of the scholarly record.

Devoted to the diagnosis, treatment, and prevention of thoracic malignancies. As a clinical lung cancer journal, it publishes original research, reviews, clinical trials, and case reports spanning non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), lung adenocarcinoma, and rare pulmonary tumors, bridging laboratory science and bedside oncology practice. The journal welcomes work across the full disease continuum: low-dose CT screening and pulmonary nodule management; molecular oncology and biomarkers including EGFR, ALK, ROS1, KRAS and FGFR alterations; targeted therapy and immune checkpoint inhibition; surgical, radiation, and systemic treatment; and survivorship. We particularly encourage studies applying artificial intelligence, deep learning, and radiomics to nodule classification, malignancy prediction, and theranostics. Intended for thoracic oncologists, pulmonologists, radiologists, pathologists, surgeons, and translational researchers, the journal advances evidence that improves clinical decision-making and patient outcomes worldwide. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, in line with COPE ethical principles.

Advances evidence across the full continuum of breast oncology, from screening and early detection to diagnosis, multimodal treatment, survivorship and the molecular biology that underpins clinical decision-making. We welcome original research, systematic reviews, narrative reviews, clinical trial reports, case reports and editorials on breast cancer diagnosis, histopathology, chemotherapy and targeted therapy, HER2-positive and triple-negative disease, endocrine therapy, metastatic breast cancer management, and image-guided interventions such as high-intensity focused ultrasound. Translational and laboratory studies on tumor biology, oxidative stress and NADPH oxidase signaling, epigenetic alterations, biomarkers and 2D/3D tumor models are equally in scope. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar and an OAI-PMH endpoint. The journal follows COPE ethical principles and charges an article-processing fee on acceptance, with waivers and discounts available.

Provides an international forum for original research, reviews, and case reports spanning the basic, translational, and clinical science of blood, blood-forming organs, and blood disorders. The journal is dedicated to advancing knowledge across the full breadth of hematology and improving the diagnosis, treatment, and understanding of hematologic disease. The journal welcomes work on anemias and red cell disorders, hematologic malignancies (leukemia, lymphoma, and myeloma), thrombosis and hemostasis, platelet and coagulation disorders, transfusion medicine and blood banking, hemoglobinopathies and sickle cell disease, hematopoiesis, bone marrow failure, and hematopoietic stem cell and cellular therapies. We publish laboratory, epidemiological, and clinical studies, including prevalence and cross-sectional research, alongside methodological and translational contributions. Manuscript types include original research articles, systematic and narrative reviews, clinical case reports, and editorials. Every submission undergoes rigorous double-blind peer review by experts in hematology and is evaluated for scientific quality, methodological soundness, and clinical relevance. All accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and are assigned a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and is exposed via an OAI-PMH endpoint for harvesting, ensuring durable citability and global reach for hematology researchers, clinicians, and trainees.